Ruxolitinib is a selective JAK1/JAK2 inhibitor424 and has been demonstrated for treating psoriasis and myeloproliferative diseases.425 Rusolitinib is generally safe in patients of RA and normal volunteers and has now completed phase 2 clinical trials (NCT00550043). The gene discussed is JAK2; the disease is rheumatoid arthritis.